DARE-19: Dapagliflozin in High-Risk Patients Hospitalized With COVID-19 – American College of Cardiology See also: Dapagliflozin in Respiratory Failure in Patients With COVID-19 – DARE-19 – American College of Cardiology   Commentaries on Twitter DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile ? Do not discontinue SGLT2i […]

The post #ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19. appeared first on Links Medicus.